Artivion, Inc. $AORT Stock Sold by Sterling Capital Management LLC

Sterling Capital Management LLC reduced its position in Artivion, Inc. (NYSE:AORT) by 96.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,513 shares of the company’s stock after selling 47,393 shares during the period. Sterling Capital Management LLC’s holdings in Artivion were worth $35,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of AORT. Royal Bank of Canada increased its position in Artivion by 73.1% during the first quarter. Royal Bank of Canada now owns 93,676 shares of the company’s stock worth $3,430,000 after buying an additional 39,553 shares during the last quarter. Legal & General Group Plc bought a new stake in Artivion in the second quarter valued at approximately $5,826,000. Orbimed Advisors LLC bought a new stake in Artivion in the first quarter valued at approximately $5,530,000. Summit Creek Advisors LLC bought a new stake in Artivion in the second quarter valued at approximately $2,704,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in shares of Artivion in the second quarter valued at approximately $3,122,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Stock Down 5.3%

Shares of AORT opened at $25.06 on Friday. Artivion, Inc. has a 52 week low of $19.16 and a 52 week high of $48.25. The firm has a market cap of $1.22 billion, a P/E ratio of -357.89 and a beta of 1.31. The firm’s 50-day simple moving average is $23.67 and its 200 day simple moving average is $29.09. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT) last issued its quarterly earnings data on Thursday, November 5th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.14. The firm had revenue of $123.79 million during the quarter, compared to the consensus estimate of $120.97 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Wall Street Zen cut Artivion from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Weiss Ratings downgraded Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Jefferies Financial Group initiated coverage on Artivion in a report on Tuesday, October 20th. They set a “buy” rating and a $31.00 price target for the company. Finally, Canaccord Genuity Group lifted their price objective on shares of Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $42.86.

More Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Revenue rose 9% year over year to $123.8 million, exceeding analyst expectations of about $121 million. Artivion Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Artivion forecast 2026 revenue of $484 million to $492 million and said it is preparing to launch its NEXUS product in January 2027, offering potential growth catalysts. Artivion outlines 2026 revenue and NEXUS launch
• Negative Sentiment: Artivion reported a GAAP net loss of $7.9 million, or $0.16 per diluted share. Non-GAAP EPS was $0.08, down from $0.16 a year earlier and below Zacks’ $0.11 consensus estimate—despite other reports citing a lower consensus benchmark. Artivion lags Q3 earnings estimates
• Negative Sentiment: Adjusted EBITDA fell 8% year over year to $22.5 million, tempering the positive revenue growth. Artivion Reports Third Quarter 2026 Financial Results

Insider Activity

In other news, CEO James Mackin sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the transaction, the chief executive officer owned 877,275 shares in the company, valued at approximately $25,397,111.25. This trade represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jean Holloway sold 977 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president owned 184,118 shares in the company, valued at approximately $5,245,521.82. This trade represents a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 90,460 shares of company stock valued at $2,557,366. 6.30% of the stock is owned by insiders.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.